{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:36:43Z","timestamp":1793371003420,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bulcan.2026.07.009","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:37:05Z","timestamp":1789119425000},"page":"1211-1223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hospitalization at home use analysis for immune checkpoint inhibitors administrations in France: Care pathways, costs and development opportunities"],"prefix":"10.1016","volume":"113","author":[{"given":"Anne-Claire","family":"Toffart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtan","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4929-8723","authenticated-orcid":false,"given":"Morgane","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9656-2432","authenticated-orcid":false,"given":"Herv\u00e9","family":"Lemasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Moreau-Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Pag\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Jolivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Panes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Chartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.07.009_bib0110","doi-asserted-by":"crossref","first-page":"875974","DOI":"10.3389\/fmed.2022.875974","article-title":"Overview of checkpoint inhibitors mechanism of action: role of immune-related adverse events and their treatment on progression of underlying cancer","volume":"9","author":"Iranzo","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.bulcan.2026.07.009_bib0115","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bulcan.2026.07.009_bib0120","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.07.009_bib0125","series-title":"Panorama des cancers en France 2025, Special 20th Anniversary Edition","year":"2025"},{"key":"10.1016\/j.bulcan.2026.07.009_bib0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bulcan.2021.09.012","article-title":"Immune checkpoint inhibitors and hospitalization at home in France","volume":"109","author":"Gobbini","year":"2022","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2026.07.009_bib0135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev-med-051022-042210","article-title":"The evolving practice of hospital at home in the United States","volume":"75","author":"Truong","year":"2024","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bulcan.2026.07.009_bib0140","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s11606-021-07065-0","article-title":"Perceptions of hospital-at-home among stakeholders: a meta-synthesis","volume":"37","author":"Chua","year":"2022","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.bulcan.2026.07.009_bib0145","series-title":"Organization and financing of public health services in Europe: country reports [Internet]","author":"Chambaud","year":"2018"},{"key":"10.1016\/j.bulcan.2026.07.009_bib0150","unstructured":"LOI no\u00a02016-41 du 26 janvier 2016 de modernisation de notre syst\u00e8me de sant\u00e9 [Law No. 2016-41 of 26 January 2016 on the modernization of the healthcare system]. Disponible \u00e0: [https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT00003191264131912641] [Acc\u00e9d\u00e9 13 May 2025]."},{"key":"10.1016\/j.bulcan.2026.07.009_bib0155","series-title":"France 2021-2030 Ten-Year Cancer Control Strategy: 2021-2025 Roadmap","year":"2021"},{"key":"10.1016\/j.bulcan.2026.07.009_bib0160","unstructured":"Haute Autorit\u00e9 de sant\u00e9 (HAS), 2015. Conditions du d\u00e9veloppement de la chimioth\u00e9rapie en hospitalisation \u00e0 domicile [Conditions for the development of chemotherapy in hospitalization at home]. Disponible \u00e0: https:\/\/www.has-sante.fr\/jcms\/c_1696038\/ [Acc\u00e9d\u00e9 13 Mai 2025]."},{"key":"10.1016\/j.bulcan.2026.07.009_bib0165","unstructured":"French Society for Immunotherapy of Cancer (FITC) (2020) Recommendations for the administration of immunotherapy in a hospital-at-home setting. Version 25 November 2020. Paris: FITC. Available at: http:\/\/www.fitcancer.fr\/wp-content\/uploads\/2020\/12\/FITC_Recommandations_immunotherapies_a_domicile.pdf (Accessed: 2 September 2026)."},{"key":"10.1016\/j.bulcan.2026.07.009_bib0170","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bulcan.2021.09.014","article-title":"Proposal for a general framework for the administration of anticancer immunotherapy in a hospital-at-home care","volume":"109","author":"Toffart","year":"2022","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2026.07.009_bib0175","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.therap.2023.01.009","article-title":"Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): how to translate guidelines into practice","volume":"78","author":"de Germay","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.bulcan.2026.07.009_bib0180","unstructured":"Agence Technique de l\u2019Information sur l\u2019Hospitalisation (ATIH), 2026. Guide m\u00e9thodologique HAD [HAD methodological guide]. Disponible \u00e0: [https:\/\/www.atih.sante.fr\/guide-methodologique-had-2026-0] [Acc\u00e9d\u00e9 10 April 2026]."},{"key":"10.1016\/j.bulcan.2026.07.009_bib0185","doi-asserted-by":"crossref","DOI":"10.1136\/thorax-2025-223974","article-title":"Health trajectories of patients with amyotrophic lateral sclerosis before and after initiation of non-invasive ventilation: a French nationwide database analysis","author":"Tank\u00e9r\u00e9","year":"2026","journal-title":"Thorax"},{"key":"10.1016\/j.bulcan.2026.07.009_bib0190","unstructured":"Toffart A-C, Casanova G, Pierre M, Lemasson H, Moreau-Mallet V, Pag\u00e8s N, et al. Place et co\u00fbts de l\u2019hospitalisation \u00e0 domicile (HAD) dans l\u2019administration des immunoth\u00e9rapies chez les patients trait\u00e9s pour un cancer en France entre 2021 et 2022, Abstract P546454, Donn\u00e9es de sant\u00e9 en vie r\u00e9elle congress, Paris, France, 20 June 2024."},{"key":"10.1016\/j.bulcan.2026.07.009_bib0195","unstructured":"Roux C (DREES). D\u00e9mographie des infirmi\u00e8res et des aides-soignantes [Demographics of nurses and nursing assistants]. 2024. Disponible \u00e0: https:\/\/drees.solidarites-sante.gouv.fr\/250619_DM14_DemographieInfirmieresAidesSoignantes [Acc\u00e9d\u00e9 13 May 2025]."},{"key":"10.1016\/j.bulcan.2026.07.009_bib0200","unstructured":"Minist\u00e8re de la Sant\u00e9, de la Famille, de l\u2019Autonomie et des Personnes handicap\u00e9es, 2022. La feuille de route 2021-2026 [The 2021-2026 roadmap]. Disponible \u00e0: https:\/\/sante.gouv.fr\/soins-et-maladies\/prises-en-charge-specialisees\/had-10951\/article\/la-feuille-de-route-2021-2026 [Acc\u00e9d\u00e9 13 May 2025]."},{"key":"10.1016\/j.bulcan.2026.07.009_bib0205","unstructured":"Centre L\u00e9on B\u00e9rard. Immunoth\u00e9rapie \u00e0 domicile, un projet innovant pour les lib\u00e9raux [Immunotherapy at home, an innovative project for private-practice nurses], 2025. Disponible \u00e0: https:\/\/www.centreleonberard.fr\/institution\/actualites\/immunotherapie-domicile-un-projet-innovant-pour-les-liberaux [Acc\u00e9d\u00e9 17 February 2025]."},{"key":"10.1016\/j.bulcan.2026.07.009_bib0210","unstructured":"Centre L\u00e9on B\u00e9rard. Immunoth\u00e9rapie \u00e0 domicile, un projet innovant pour les lib\u00e9raux [Immunotherapy at home, an innovative project for private-practice nurses], 2025. Disponible \u00e0: https:\/\/www.centreleonberard.fr\/institution\/actualites\/immunotherapie-domicile-un-projet-innovant-pour-les-liberaux [Acc\u00e9d\u00e9 17 February 2025]."}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:26:20Z","timestamp":1793370380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126003838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0007455126003838"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.009","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hospitalization at home use analysis for immune checkpoint inhibitors administrations in France: Care pathways, costs and development opportunities","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}